<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Prev Med Rep</journal-id><journal-id journal-id-type="iso-abbrev">Prev Med Rep</journal-id><journal-title-group><journal-title>Preventive Medicine Reports</journal-title></journal-title-group><issn pub-type="epub">2211-3355</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26844072</article-id><article-id pub-id-type="pmc">4721453</article-id><article-id pub-id-type="publisher-id">S2211-3355(15)00029-7</article-id><article-id pub-id-type="doi">10.1016/j.pmedr.2015.03.004</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Cost-effectiveness of retreatment with varenicline after failure with or relapse after initial treatment for smoking cessation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Annemans</surname><given-names>Lieven</given-names></name><xref rid="af0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Marbaix</surname><given-names>Sophie</given-names></name><email>sophie.marbaix@pfizer.com</email><xref rid="af0010" ref-type="aff">b</xref><xref rid="cr0005" ref-type="corresp">&#x0204e;</xref></contrib><contrib contrib-type="author"><name><surname>Nackaerts</surname><given-names>Kristiaan</given-names></name><xref rid="af0015" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Bartsch</surname><given-names>Pierre</given-names></name><xref rid="af0020" ref-type="aff">d</xref></contrib></contrib-group><aff id="af0005"><label>a</label>Ghent University, Department of Public Health, Gent, Belgium</aff><aff id="af0010"><label>b</label>Pfizer, Department of Health and Value, Brussels, Belgium</aff><aff id="af0015"><label>c</label>KU Leuven, Leuven University, University Hospitals Leuven, Department of Pulmonology, Respiratory Oncology Unit, Leuven, Belgium</aff><aff id="af0020"><label>d</label>Li&#x000e8;ge University Hospital, Department of Pneumology, Pneumology and Smoking Cessation Unit, Li&#x000e8;ge, Belgium</aff><author-notes><corresp id="cr0005"><label>&#x0204e;</label>Corresponding author. Fax: +&#x000a0;32 2 554 66 91. <email>sophie.marbaix@pfizer.com</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>14</day><month>3</month><year>2015</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><year>2015</year></pub-date><pub-date pub-type="epub"><day>14</day><month>3</month><year>2015</year></pub-date><volume>2</volume><fpage>189</fpage><lpage>195</lpage><permissions><copyright-statement>&#x000a9; 2015 The Authors</copyright-statement><copyright-year>2015</copyright-year><license license-type="CC BY-NC-ND" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/"><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><abstract><sec><title>Objectives</title><p>A recent trial showed the clinical benefit of retreatment with varenicline in subjects failing on the initial treatment, or relapsing after initial success. The objective of this study was to evaluate the cost-effectiveness of retreatment with varenicline compared with other smoking cessation interventions.</p></sec><sec><title>Methods</title><p>A published Markov model was adapted to compare one quit attempt of varenicline followed by retreatment to treatment/retreatment with nicotine replacement therapy (NRT), bupropion or placebo, and with only 1 quit attempt of varenicline. Efficacy was obtained from clinical trials. Incidence of smoking-related diseases was based on published data. Cost of therapies and complications was obtained from databases and literature.</p></sec><sec><title>Results</title><p>For 1000 smokers willing to quit, varenicline retreatment saves 275,000&#x020ac;, 118,000&#x020ac;, 316,000&#x020ac; and 237,000&#x020ac; compared to NRT, bupropion, placebo, or one single varenicline quit attempt respectively at lifetime and from the healthcare payer perspective. The number of quality adjusted life years gained is 74, 63, 193 and 111 respectively. Sensitivity analyses showed the robustness of these findings.</p></sec><sec><title>Conclusion</title><p>This analysis suggests that in the long term, varenicline retreatment is a dominant intervention, meaning both greater health gains and greater costs saved, over other possible interventions and therefore should be considered as a standard option.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>Smoking cessation</kwd><kwd>Retreatment</kwd><kwd>Varenicline</kwd><kwd>Nicotine replacement therapy</kwd><kwd>Bupropion</kwd><kwd>Cost-effectiveness</kwd></kwd-group></article-meta></front><body><sec id="s0005"><title>Introduction</title><p>Smoking cessation (SC) therapies are widely available in Europe and many are reimbursed by public health care payers (<xref rid="bb0030" ref-type="bibr">Aubin et al., 2014</xref>).</p><p>Smoking cessation is aimed at preventing severe complications associated with smoking, including COPD, lung cancer, coronary heart diseases (CHD), stroke and asthma exacerbations. It is well established that the lifespan of a smoker is shorter than that of a non-smoker, with a difference of 6 to 10&#x000a0;years, on average, depending on the number of cigarettes smoked (<xref rid="bb0245" ref-type="bibr">Van den Bruel et al., 2004</xref>).</p><p>Varenicline, nicotine replacement therapy (NRT) and bupropion are the current standard pharmacological interventions to aid in smoking cessation. In motivated subjects, starting a treatment with one of these therapies is justified in association with behavioral counseling. However, smoking cessation is difficult and relapse is common among individuals attempting to quit (<xref rid="bb0090" ref-type="bibr">Fiore et al., 2000</xref>).</p><p>A recent trial assessing the efficacy of varenicline retreatment in subjects unsuccessful after a first attempt showed a success rate (defined as continuous abstinence from 9&#x02013;52&#x000a0;weeks) of 20.1% (<xref rid="bb0105" ref-type="bibr">Gonzales et al., 2014</xref>).</p><p>In the current health care environment, the need to allocate public finances has increased the interest in cost-effectiveness research (<xref rid="bb0010" ref-type="bibr">Annemans et al., 2011</xref>) and reimbursement of medicines does not only require clinical effectiveness but also cost-effectiveness.</p><p>The objective of this study was to estimate the cost-effectiveness of varenicline in retreatment compared to other possible retreatment options including no treatment, and retreatment with bupropion or NRT.</p></sec><sec id="s0010"><title>Methods</title><sec id="s0015"><title>General aspects</title><p>The perspective of this analysis is the healthcare payer perspective: the public health care payer (Rijksinstituut voor ziekte &#x02014; en invaliditeitsverzekering/Institut National d'Assurance Maladie-Invalidit&#x000e9; &#x02014; RIZIV/INAMI) and the patient. This combined perspective follows the recommendations of the Belgian Health Technology Assessment (HTA) body KCE (Kenniscentrum&#x02014;Centre d'expertise) (<xref rid="bb0070" ref-type="bibr">Cleemput et al., 2012</xref>) and gives a complete picture of smoking cessation since NRT is not reimbursed by the public health insurance. Given this chosen perspective only direct health care costs are included.</p></sec><sec id="s0020"><title>Decision model</title><p>The Two-quit BENESCO (Benefit of Smoking Cessation on Outcomes) model is based on an adaptation of the original BENESCO model, a Markov model that was developed to assess the cost-effectiveness of one quit attempt with smoking cessation interventions (<xref rid="bb0125" ref-type="bibr">Howard et al., 2008</xref>). The BENESCO model simulates the incidence of smoking-related morbidity and mortality over time and is an extension of the HECOS (Health Economic Consequences of Smoking) model that was used by the World Health Organization European Partnership Project to reduce tobacco dependence (<xref rid="bb0195" ref-type="bibr">Orme et al., 2001</xref>). BENESCO model has also been reviewed in various health technology assessments. This model has been customized for various countries, including Belgium, and the results have been widely published (<xref rid="bb0120" ref-type="bibr">Hoogendoorn et al., 2008</xref>, <xref rid="bb0085" ref-type="bibr">Fern&#x000e1;ndez de Bobadilla Osorio et al., 2008</xref>, <xref rid="bb0045" ref-type="bibr">Bolin et al., 2008</xref>, <xref rid="bb0015" ref-type="bibr">Annemans et al., 2009</xref>, <xref rid="bb0130" ref-type="bibr">Igarashi et al., 2009</xref>, <xref rid="bb0035" ref-type="bibr">Bae et al., 2009</xref>, <xref rid="bb0160" ref-type="bibr">Linden et al., 2010</xref>, <xref rid="bb0020" ref-type="bibr">Athanasakis et al., 2012</xref>, <xref rid="bb0170" ref-type="bibr">Lutz et al., 2012</xref>). These analyses were also included in systematic reviews about the cost-effectiveness of varenicline (<xref rid="bb0145" ref-type="bibr">Keating and Lyseng-Williamson, 2010</xref>, <xref rid="bb0270" ref-type="bibr">Zimovetz et al., 2011</xref>, <xref rid="bb0165" ref-type="bibr">Mahmoudi et al., 2012</xref>).</p><p>The Two-quit BENESCO model follows a simulated cohort of 1000 Belgian smokers from first quit attempt through retreatment among those who were initially not successful or who relapsed, until all members of the cohort have either died or reached the age of 100 (<xref rid="f0005" ref-type="fig">Fig.&#x000a0;1</xref>). Lifetime clinical and economic outcomes of an initial quit attempt with varenicline followed by retreatment with varenicline, if the patient fails with or relapses after initial treatment (=&#x000a0;2QA varenicline) are simulated and compared with the alternative interventions:<list list-type="simple"><list-item id="u0005"><label>&#x02022;</label><p>1 quit attempt with nicotine replacement therapy (NRT) followed by NRT retreatment in case of failure or relapse (=&#x000a0;2QA NRT)</p></list-item><list-item id="u0010"><label>&#x02022;</label><p>1 quit attempt with bupropion followed by bupropion retreatment in case of failure or relapse (=&#x000a0;2QA bupropion)</p></list-item><list-item id="u0015"><label>&#x02022;</label><p>1 quit attempt with placebo followed by placebo retreatment in case of failure or relapse (=&#x000a0;2QA placebo)</p></list-item><list-item id="u0020"><label>&#x02022;</label><p>Only 1 quit attempt with varenicline followed by 1 quit attempt with placebo (1QA varenicline).</p></list-item></list></p><p>As in the initial BENESCO model, this model allows transitions to the smoking-related diseases as described in <xref rid="f0010" ref-type="fig">Fig.&#x000a0;2</xref>. A cycle length of one year was chosen because the abstinence rate is measured at 1&#x000a0;year in the clinical trials. Moreover, the benefits of smoking cessation interventions are apparent only up to several years after cessation, which makes a shorter cycle length not useful. All subjects entering the model are smokers, with co-morbidities according to their baseline prevalence among smokers. In the first year, subjects in the cohort receive initial smoking cessation treatment. At the end of each year, subjects transition between 3 smoking states (smoker, recent quitter, long term quitter), each of which can be further defined in terms of the presence or absence of the mentioned smoking-related diseases.</p><p>Subjects are considered recent quitters if abstinent for 2&#x02013;5&#x000a0;years after successful quit attempt and long term quitters after more than 5&#x000a0;years of abstinence. Health benefits of cessation are applied to all quitters, although risk of relapse remains (<xref rid="bb0080" ref-type="bibr">Feenstra et al., 2005</xref>, <xref rid="bb0250" ref-type="bibr">van Genugten et al., 2003</xref>). Furthermore all subjects who fail during first quit attempt or relapse after first quit attempt will attempt a second quit. The evaluation of treatment failure or relapse occurs at the end of each cycle.</p><p><xref rid="f0010" ref-type="fig">Fig.&#x000a0;2</xref> illustrates the order of the smoking-related diseases in the BENESCO model. By modeling the morbidities in this way, a patient can have, for example, one or more asthma exacerbations, followed by CHD or stroke with one or more acute events, followed by lung cancer or COPD. Death can occur at any time, and its cause is specified. If subjects have one of the two acute morbidities (CHD or stroke) they cannot develop the other. Similarly if subjects develop one of the two chronic complications (lung cancer or COPD) they cannot develop the other. Subjects can progress from an acute disease to chronic, but not the other way. If subjects progress from an acute disease to a chronic one, their acute disease is ignored from that point forward.</p></sec><sec id="s0025"><title>Health data input</title><p>The abstinence rates of the various smoking cessation interventions were derived from a recent Cochrane systematic review (<xref rid="bb0055" ref-type="bibr">Cahill et al., 2013</xref>) as well as from the results of the randomized clinical trial on varenicline treatment/retreatment. In the absence of efficacy data of NRT and bupropion at 52&#x000a0;weeks in retreatment trials, we have conservatively used the same value in the retreatment as in the first treatment for these 2 interventions. As in the initial BENESCO model, the current model does not consider the adverse events related to the SC interventions because clinical trial data do not indicate sustained comparative difference between interventions that would impact on outcomes.</p><p>The clinical data are shown in <xref rid="t0005" ref-type="table">Table&#x000a0;1</xref>.</p><p>The annual relapse rate for abstinent subjects is 6% (<xref rid="bb0260" ref-type="bibr">Wetter et al., 2004</xref>), and this rate is applied to recent quitters each year in the period of 2&#x02013;5&#x000a0;years. If after 5&#x000a0;years the subject is still abstinent, then the risk of relapsing to smoking is reduced to 2% annually for the next 5&#x000a0;years (years 6&#x02013;10) (<xref rid="bb0155" ref-type="bibr">Krall et al., 2002</xref>). In the subjects that maintain abstinence through 10&#x000a0;years following their quit attempt, the relapse rate is reduced to 1% annually.</p><p>The hazard ratios of dying from smoking-related diseases (<xref rid="bb0225" ref-type="bibr">Thun et al., 2000</xref>) have been used as a proxy for the relative risk (RR) of the incidence and prevalence of smoking-related diseases (<xref rid="bb0125" ref-type="bibr">Howard et al., 2008</xref>, <xref rid="bb0195" ref-type="bibr">Orme et al., 2001</xref>). The RRs vary with age, gender and smoking status, as in the analysis by <xref rid="bb0225" ref-type="bibr">Thun et al. (2000)</xref> already used for the initial BENESCO model (<xref rid="t0010" ref-type="table">Table&#x000a0;2</xref>).</p><p>The RR of smoking-related diseases for subjects who remain smokers at the end of the cycle is assumed to be the same as that of a current smoker. The RRs of a recent quitter are assumed to be equal to RRs of former smokers and RRs of long-term quitters are assumed to be equal to RRs of never-smokers. The lung cancer risk for long-term quitters has been kept equal to the risk in recent quitters over lifetime.</p><p>The transition probabilities to smoking-related diseases have been calculated, by smoking status, based on these RRs and the prevalence, incidence and mortality cases of each smoking-related disease by age and gender.</p></sec><sec id="s0030"><title>Cost data input</title><p>Hospitalization costs of smoking-related diseases were obtained from the Belgian TCT database (<xref rid="bb0215" ref-type="bibr">2010, tct.fgov.be</xref>). This national database provides the average cost per hospital stay for all APR-DRGs (All Patients Refined Diagnosis Related Group) paid by the public health insurance and the patient (co-payment).</p><p>The annual follow-up cost for smoking-related diseases was taken from literature (<xref rid="bb0005" ref-type="bibr">Annemans et al., 2003</xref>, <xref rid="bb0185" ref-type="bibr">Muls et al., 1998</xref>, <xref rid="bb0200" ref-type="bibr">Pacolet et al., 2011</xref>, <xref rid="bb0050" ref-type="bibr">Caekelbergh et al., 2005</xref>).</p><p>Drug costs were taken from the <xref rid="bb0135" ref-type="bibr">RIZIV/INAMI</xref> database for reimbursed drugs (<ext-link ext-link-type="uri" xlink:href="http://www.riziv.fgov.be" id="ir9115">www.riziv.fgov.be</ext-link>) , and from the CBIP (<xref rid="bb0065" ref-type="bibr">Centre Belge d'Information Pharmacoth&#x000e9;rapeutique</xref>) for non-reimbursed drugs, in 2013. The mean daily cost of the NRTs was estimated based on a mean daily intake from the &#x02018;Fiche de Transparence June 2008&#x02019; on the CBIP website (<ext-link ext-link-type="uri" xlink:href="http://www.cbip.be" id="ir0115">www.cbip.be</ext-link>). A mean treatment duration of 12&#x000a0;weeks was applied.</p><p>Cost inputs and their sources were validated through discussion with a group of Belgian clinicians during an Advisory Board: in particular, agreement was reached on data source for average daily intake and duration of the smoking cessation interventions.</p><p>All costs from years prior to 2013 were inflated with the health index of December 2013 (<ext-link ext-link-type="uri" xlink:href="http://www.mineco.fgov.be" id="ir0120">www.mineco.fgov.be</ext-link>). Discount rates of 3% and 1.5% were applied to future costs and health benefits, consistent with Belgian guidelines (<xref rid="bb0070" ref-type="bibr">Cleemput et al., 2012</xref>).</p><p>Cost data are reported in <xref rid="t0015" ref-type="table">Table&#x000a0;3</xref>.</p></sec><sec id="s0035"><title>Utilities</title><p>To calculate QALYs (Quality Adjusted Life Years), the BENESCO model utilizes utility weights for smoking-related diseases. For COPD and lung cancer, utility weights were applied for the first year and for subsequent years. For CHD, stroke, and asthma exacerbations, each initial and subsequent event leads to a utility decrease in only the cycle that the event occurs (<xref rid="t0020" ref-type="table">Table&#x000a0;4</xref>).</p><p>The baseline utility values for the general population and the utility weights for the smoking-related diseases were the same as those reported in the Belgian customization of initial BENESCO model (<xref rid="bb0015" ref-type="bibr">Annemans et al., 2009</xref>).</p></sec><sec id="s0040"><title>Sensitivity analysis</title><p>One-way univariate sensitivity analyses and a probabilistic sensitivity analysis (PSA) were performed. The latter included uncertainty around effectiveness, costs of complications, and utilities. Time horizon, population characteristics and model settings were kept constant. Probability distributions are selected based on the specific parameter type according to standard practice (<xref rid="bb0110" ref-type="bibr">Gray et al., 2010</xref>).</p><p>The parameters along with the distribution used are shown in the Technical <xref rid="s0070" ref-type="sec">Appendix A</xref>.</p></sec><sec id="s0045"><title>Model validation</title><p>Quality assurance was conducted for all structural changes made to the original BENESCO model, as well as for scenario testing and face validity checks of model results.</p><p>This validation process was conducted by PAREXEL-HERON, developer of the initial BENESCO model and this Two-quit update.</p></sec></sec><sec id="s0050"><title>Results</title><p>The base case results are shown in <xref rid="t0025" ref-type="table">Table&#x000a0;5</xref>. When compared to other treatment/retreatment interventions, varenicline retreatment (2QA) provides both the greatest health benefits (QALYs gained) as well as cost savings in the long term. For 1000 smokers willing to quit smoking, 2QA varenicline saves respectively 275,000&#x020ac;, 118,000&#x020ac;, 316,000&#x020ac; and 237,000&#x020ac; as compared to two courses of NRT (2QA), bupropion (2QA), placebo (2 QA placebo) or one single varenicline (1QA varenicline) treatment at lifetime. The number of QALYs gained is 74, 63, 193 and 111 respectively.</p><p>In univariate sensitivity analyses, discount rates (from 0% up to 5% on both costs and effects), cost of NRT and relative risk for smoking-related diseases in long term quitters were the most influential parameters, though changes did not affect the conclusions. The probabilistic sensitivity analysis illustrated in <xref rid="f0015" ref-type="fig">Fig.&#x000a0;3</xref> provides evidence for the robustness of the model results.</p></sec><sec id="s0055"><title>Discussion</title><p>The current analysis assesses the cost-effectiveness of a quit attempt with varenicline followed by a retreatment with varenicline in the motivated smoker who failed or relapsed after at least one year since initial treatment. This intervention has been compared with: (1) 1 quit attempt with NRT followed by retreatment with NRT, (2) 1 quit attempt with bupropion followed by retreatment with bupropion, (3) 1 quit attempt with placebo followed by retreatment with placebo, and (4) only 1 quit attempt with varenicline.</p><p>The effectiveness of varenicline treatment/retreatment translates into benefits of reduced incidence of smoking-related diseases and deaths, and increased cumulative Life Years and Quality Adjusted Life Years. These gains are most impacted by avoiding morbidity, especially due to a predicted reduction of COPD incidence, and avoiding mortality, primarily due to COPD and lung cancer. The decreased incidence of smoking-related diseases translates into additional health care savings, which largely offset the cost associated with varenicline treatment.</p><p>The model outcomes suggest net saving and net health benefits for 2QA varenicline over lifetime, making it a cost-saving intervention. This finding results from the higher efficacy of varenicline compared to the other smoking cessation interventions.</p><p>This analysis is the first one to consider adaptation of the BENESCO model with a second quit attempt. The initial BENESCO model has been customized for many countries, leading to similar outcomes based on same comparators and time horizon (<xref rid="bb0145" ref-type="bibr">Keating and Lyseng-Williamson, 2010</xref>, <xref rid="bb0270" ref-type="bibr">Zimovetz et al., 2011</xref>, <xref rid="bb0165" ref-type="bibr">Mahmoudi et al., 2012</xref>). We might expect similar conclusions when considering 2QA varenicline in other settings. However, this needs to be further confirmed.</p><p>The study limitations should be noted. First, only the efficacy of the smoking cessation interventions is considered, with no consideration of the impact of possible adverse events. However, the earlier mentioned meta-analysis of available published data has shown that the likelihood of adverse events associated with varenicline, NRT and bupropion is very limited (<xref rid="bb0055" ref-type="bibr">Cahill et al., 2013</xref>) and consequently their impact on utilities and costs should be minimal. The good cardiovascular and neuropsychiatric safety profile of varenicline has also recently been confirmed in clinical trials (<xref rid="bb0255" ref-type="bibr">Ware et al., 2013</xref>, <xref rid="bb0280" ref-type="bibr">Gibbons and Mann, 2013</xref>, <xref rid="bb0180" ref-type="bibr">Mills et al., 2014</xref>).</p><p>Secondly, similar to the initial BENESCO model, this model only includes 5 smoking-related diseases keeping co-morbidities to a minimum. Modeling all the possible multiple-disease risks and scenarios would not only greatly increase the complexity of the model but would also increase the quantity of data required. This more simplified model is a conservative approach because it captures only five smoking-related diseases with a high impact to the healthcare system, and does not vary the risks of other diseases based on subjects' morbidity history. Thirdly, all RRs for smoking-related diseases, as derived from <xref rid="bb0225" ref-type="bibr">Thun et al. (2000)</xref> have been kept constant for each smoking status. This may be perceived, in some cases, as a simplification of reality. As such, the model considers that long term quitters (namely quitter for more than 5&#x000a0;years) benefit from constant former smokers' RR for lung cancer as from year 6 until their death. <xref rid="bb9000" ref-type="bibr">Peto et al. (2000)</xref> described a more progressive decrease in the risk of lung cancer as the time of abstinence increases. Yet, comparing our input values with the values referred in <xref rid="bb9000" ref-type="bibr">Peto et al. (2000)</xref>, our outcomes are more conservative. This assumption has also been tested in the deterministic and probabilistic sensitivity analyses.</p><p>Other published studies have examined the cost-effectiveness of varenicline for smoking cessation in the Belgian population, using the same model as the one on which the current one is built (<xref rid="bb0015" ref-type="bibr">Annemans et al., 2009</xref>, <xref rid="bb0040" ref-type="bibr">Bolin et al., 2009</xref>, <xref rid="bb0150" ref-type="bibr">Knight et al., 2012</xref>, <xref rid="bb0265" ref-type="bibr">Wilson et al., 2010</xref>). The key way in which these studies differ from the present analysis is the number of quit attempts over the subjects' lifetime: previous studies only considered one quit attempt, while the present analysis considers up to two quit attempts with the same intervention.</p><p>The published studies also differ from the current analysis in terms of the clinical data sources used, in particular the efficacy data of the interventions. <xref rid="bb0015" ref-type="bibr">Annemans and colleagues (2009)</xref> obtained 52&#x000a0;week abstinence rates for varenicline, bupropion, and placebo from pooling the results of two comparative trials (<xref rid="bb0100" ref-type="bibr">Gonzales et al., 2006</xref>, <xref rid="bb0140" ref-type="bibr">Jorenby et al., 2006</xref>). <xref rid="bb0040" ref-type="bibr">Bolin and colleagues (2009)</xref> derived efficacy data from a single randomized open-label trial that compared varenicline to NRT (<xref rid="bb0025" ref-type="bibr">Aubin et al., 2008</xref>). <xref rid="bb0150" ref-type="bibr">Knight et al. (2012)</xref> derived efficacy data from an RCT that compared a standard course of treatment with an additional 12&#x000a0;week maintenance course (<xref rid="bb0230" ref-type="bibr">Tonstad et al., 2006</xref>). The current study used efficacy data from a large systematic review and meta-analysis that considered 267 studies (not all for the interventions considered in the current analysis) to derive the first quit attempt efficacies of all SC interventions (<xref rid="bb0055" ref-type="bibr">Cahill et al., 2013</xref>). These studies all provide similar cost-effectiveness results, namely that varenicline dominates NRT, bupropion and placebo, meaning it is less costly and more effective over time. These findings are expected given the greater efficacy in quitting of varenicline over the other smoking cessation interventions.</p><p>Models are always a simple reflection of reality and subject to uncertainties. In order to assess the uncertainty in the current model parameters, a PSA was performed where the parameters such as the effectiveness of the smoking cessation interventions, the treatment costs of diseases, and the utilities associated with each health state were varied according to established distributions (<xref rid="bb0110" ref-type="bibr">Gray et al., 2010</xref>). For every treatment comparison, the PSA results confirmed that varenicline significantly dominated, meaning it was less costly and more effective than the comparator. The same conclusion was drawn based on one way sensitivity/scenario analyses on discount rate (from 0% up to 5% on both costs and effects), cost of NRT and relative risk for smoking-related diseases in long term quitters.</p><p>A final comment may be related to the perspective of the study which did not take into account the productivity-related costs, likely leading to an underestimation of the economic benefits of 2QA varenicline.</p></sec><sec id="s0060"><title>Conclusion</title><p>Tobacco dependence is a chronic condition and successfully quitting smoking is extremely difficult. This Two-quit BENESCO model demonstrates that retreatment with varenicline in case of failure with or relapse after initial treatment is a cost-saving option versus no retreatment and versus other retreatment interventions. It supports the conclusion that fully supporting smokers in their attempts to quit smoking is an economically justified strategy.</p></sec><sec id="s0065"><title>Conflict of interest</title><p>PAREXEL-HERON received funding from Pfizer to develop the model. Lieven Annemans was a paid consultant to Pfizer in connection with the development of this manuscript. Prof. K. Nackaerts reports funding and nonfinancial support from Pfizer during the conduct of varenicline clinical studies and personal fees from Pfizer (Belgium) outside the submitted work, for serving as an advisory board member and for lectures. Prof. P. Bartsch reports funding from Pfizer (Belgium) outside the submitted work, for serving as an advisory board member. Sophie Marbaix is a Pfizer Belgium/Luxembourg employee.</p><p>All authors have reviewed and approved the final content of this manuscript.</p></sec></body><back><ref-list><title>References</title><ref id="bb0005"><element-citation publication-type="journal" id="rf0005"><person-group person-group-type="author"><name><surname>Annemans</surname><given-names>L.</given-names></name><name><surname>Lamotte</surname><given-names>M.</given-names></name><name><surname>Levy</surname><given-names>E.</given-names></name></person-group><article-title>Cost effectiveness analysis of clopidogrel versus aspirin in patients with atherothrombosis based on the CAPRIE trial</article-title><source>J. Med. Econ.</source><volume>6</volume><year>2003</year><fpage>55</fpage><lpage>68</lpage></element-citation></ref><ref id="bb0015"><element-citation publication-type="journal" id="rf0015"><person-group person-group-type="author"><name><surname>Annemans</surname><given-names>L.</given-names></name><name><surname>Nackaerts</surname><given-names>K.</given-names></name><name><surname>Bartsch</surname><given-names>P.</given-names></name></person-group><article-title>Cost-effectiveness of varenicline in Belgium, compared with bupropion, nicotine replacement therapy, brief counselling and unaided smoking cessation: a BENESCO Markov cost-effectiveness analysis</article-title><source>Clin. Drug Investig.</source><volume>1</volume><year>2009</year><fpage>655</fpage><lpage>665</lpage></element-citation></ref><ref id="bb0010"><element-citation publication-type="journal" id="rf0010"><person-group person-group-type="author"><name><surname>Annemans</surname><given-names>L.</given-names></name><name><surname>Cleemput</surname><given-names>I.</given-names></name><name><surname>Hulstaert</surname><given-names>F.</given-names></name><name><surname>Simoens</surname><given-names>S.</given-names></name></person-group><article-title>Stimulating pharmaceutical innovation in the EU</article-title><source>Expert Rev. Pharmacoecon. Outcomes Res.</source><volume>11</volume><issue>3</issue><year>2011</year><fpage>235</fpage><lpage>239</lpage><pub-id pub-id-type="pmid">21671690</pub-id></element-citation></ref><ref id="bb0020"><element-citation publication-type="journal" id="rf0020"><person-group person-group-type="author"><name><surname>Athanasakis</surname><given-names>K.</given-names></name><name><surname>Igoumenidis</surname><given-names>M.</given-names></name><name><surname>Karampli</surname><given-names>E.</given-names></name><name><surname>Vitsou</surname><given-names>E.</given-names></name><name><surname>Sykara</surname><given-names>G.</given-names></name><name><surname>Kyriopoulos</surname><given-names>J.</given-names></name></person-group><article-title>Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece</article-title><source>Clin. Ther.</source><volume>34</volume><issue>8</issue><year>2012</year><fpage>1803</fpage><lpage>1814</lpage><comment>(Aug)</comment><pub-id pub-id-type="pmid">22818870</pub-id></element-citation></ref><ref id="bb0025"><element-citation publication-type="journal" id="rf0025"><person-group person-group-type="author"><name><surname>Aubin</surname><given-names>H.J.</given-names></name><name><surname>Bobak</surname><given-names>A.</given-names></name><name><surname>Britton</surname><given-names>R.</given-names></name></person-group><article-title>Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial</article-title><source>Thorax</source><volume>63</volume><year>2008</year><fpage>717</fpage><lpage>724</lpage><pub-id pub-id-type="pmid">18263663</pub-id></element-citation></ref><ref id="bb0030"><element-citation publication-type="journal" id="rf0030"><person-group person-group-type="author"><name><surname>Aubin</surname><given-names>H.J.</given-names></name><name><surname>Luquiens</surname><given-names>A.</given-names></name><name><surname>Berlin</surname><given-names>I.</given-names></name></person-group><article-title>Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice</article-title><source>Br. J. Clin. Pharmacol.</source><volume>77</volume><issue>2</issue><year>2014</year><fpage>324</fpage><lpage>336</lpage><pub-id pub-id-type="pmid">23488726</pub-id></element-citation></ref><ref id="bb0035"><element-citation publication-type="journal" id="rf0190"><person-group person-group-type="author"><name><surname>Bae</surname><given-names>J.Y.</given-names></name><name><surname>Kim</surname><given-names>C.H.</given-names></name><name><surname>Lee</surname><given-names>E.K.</given-names></name></person-group><article-title>Evaluation of cost-utility of varenicline compared with existing smoking cessation therapies in South Korea</article-title><source>Value Health</source><volume>12</volume><issue>Suppl. 3</issue><year>2009</year><fpage>S70</fpage><lpage>S73</lpage><comment>(Nov&#x02013;Dec)</comment><pub-id pub-id-type="pmid">20586986</pub-id></element-citation></ref><ref id="bb0045"><element-citation publication-type="journal" id="rf0195"><person-group person-group-type="author"><name><surname>Bolin</surname><given-names>K.</given-names></name><name><surname>M&#x000f6;rk</surname><given-names>A.C.</given-names></name><name><surname>Willers</surname><given-names>S.</given-names></name><name><surname>Lindgren</surname><given-names>B.</given-names></name></person-group><article-title>Varenicline as compared to bupropion in smoking-cessation therapy &#x02014; cost-utility results for Sweden 2003</article-title><source>Respir. Med.</source><volume>102</volume><year>2008</year><fpage>699</fpage><lpage>710</lpage><pub-id pub-id-type="pmid">18289839</pub-id></element-citation></ref><ref id="bb0040"><element-citation publication-type="journal" id="rf0200"><person-group person-group-type="author"><name><surname>Bolin</surname><given-names>K.</given-names></name><name><surname>Wilson</surname><given-names>K.</given-names></name><name><surname>Benhaddi</surname><given-names>H.</given-names></name></person-group><article-title>Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation &#x02014; results from four European countries</article-title><source>Eur. J. Pub. Health</source><volume>19</volume><issue>6</issue><year>2009</year><fpage>650</fpage><lpage>654</lpage><pub-id pub-id-type="pmid">19491286</pub-id></element-citation></ref><ref id="bb0050"><element-citation publication-type="book" id="rf0205"><person-group person-group-type="author"><name><surname>Caekelbergh</surname><given-names>K.</given-names></name><name><surname>Spaepen</surname><given-names>E.</given-names></name><name><surname>Annemans</surname><given-names>L.</given-names></name></person-group><chapter-title>Management of COPD in Belgium: a real life cost of illness [poster]</chapter-title><source>ISPOR 8th Annual European Congress, 2005 Nov 6&#x02013;8, Florence</source><year>2005</year></element-citation></ref><ref id="bb0055"><element-citation publication-type="journal" id="rf0210"><person-group person-group-type="author"><name><surname>Cahill</surname><given-names>K.</given-names></name><name><surname>Stevens</surname><given-names>S.</given-names></name><name><surname>Perera</surname><given-names>R.</given-names></name><name><surname>Lancaster</surname><given-names>T.</given-names></name></person-group><article-title>Pharmacological interventions for smoking cessation: an overview and network meta-analysis</article-title><source>Cochrane Database Syst. Rev.</source><year>2013</year><comment>(Issue 5. Art. No: CD009329)</comment></element-citation></ref><ref id="bb0060"><element-citation publication-type="journal" id="rf0045"><person-group person-group-type="author"><name><surname>Cassino</surname><given-names>C.</given-names></name><name><surname>Ito</surname><given-names>K.</given-names></name><name><surname>Bader</surname><given-names>I.</given-names></name></person-group><article-title>Cigarette smoking and ozone-associated emergency department use for asthma by adults in New York City</article-title><source>Am. J. Respir. Crit. Care Med.</source><volume>159</volume><issue>6</issue><year>1999</year><fpage>1773</fpage><lpage>1779</lpage><pub-id pub-id-type="pmid">10351917</pub-id></element-citation></ref><ref id="bb0065"><element-citation publication-type="other" id="rf0215"><article-title>Centre Belge d'Information Pharmacoth&#x000e9;rapeutique (CBIP-BCFI)</article-title><comment>Available from URL:</comment><ext-link ext-link-type="uri" xlink:href="http://www.cbip.be" id="ir0125">http://www.cbip.be</ext-link><comment>(online. Accessed October 2013)</comment></element-citation></ref><ref id="bb0070"><element-citation publication-type="book" id="rf0220"><person-group person-group-type="author"><name><surname>Cleemput</surname><given-names>I.</given-names></name><name><surname>Neyt</surname><given-names>M.</given-names></name><name><surname>Van de Sande</surname><given-names>S.</given-names></name><name><surname>Thiry</surname><given-names>N.</given-names></name></person-group><chapter-title>Belgian guidelines for economic evaluations and budget impact analyses: second edition</chapter-title><source>KCE Reports 183C 2012</source><year>2012</year></element-citation></ref><ref id="bb0075"><element-citation publication-type="journal" id="rf0050"><person-group person-group-type="author"><name><surname>Duncan</surname><given-names>P.W.</given-names></name><name><surname>Lai</surname><given-names>S.M.</given-names></name><name><surname>Keighley</surname><given-names>J.</given-names></name></person-group><article-title>Defining post-stroke recovery: implications for design and interpretation of drug trials</article-title><source>Neuropharmacology</source><volume>39</volume><issue>5</issue><year>2000</year><fpage>835</fpage><lpage>841</lpage><pub-id pub-id-type="pmid">10699448</pub-id></element-citation></ref><ref id="bb0080"><element-citation publication-type="journal" id="rf0225"><person-group person-group-type="author"><name><surname>Feenstra</surname><given-names>T.L.</given-names></name><name><surname>Hamberg-van Reenen</surname><given-names>H.H.</given-names></name><name><surname>Hoogenveen</surname><given-names>R.T.</given-names></name><name><surname>Rutten-van Molken</surname><given-names>M.P.</given-names></name></person-group><article-title>Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic modeling study</article-title><source>Value Health</source><volume>8</volume><issue>3</issue><year>2005</year><fpage>178</fpage><lpage>190</lpage><pub-id pub-id-type="pmid">15877590</pub-id></element-citation></ref><ref id="bb0085"><element-citation publication-type="journal" id="rf0230"><person-group person-group-type="author"><name><surname>Fern&#x000e1;ndez de Bobadilla Osorio</surname><given-names>J.</given-names></name><name><surname>S&#x000e1;nchez-Maestre</surname><given-names>C.</given-names></name><name><surname>Brosa Riestra</surname><given-names>M.</given-names></name><name><surname>Arroyo</surname><given-names>O.</given-names></name><name><surname>Sanz de Burgoa</surname><given-names>V.</given-names></name><name><surname>Wilson</surname><given-names>K.</given-names></name></person-group><article-title>Cost effectiveness analysis of varenicline (Champix) for the treatment of smoking in Spain</article-title><source>An. Med. Interna</source><volume>25</volume><issue>7</issue><year>2008</year><fpage>342</fpage><lpage>348</lpage><comment>(Jul, Spanish)</comment><pub-id pub-id-type="pmid">19295994</pub-id></element-citation></ref><ref id="bb0090"><element-citation publication-type="book" id="rf0235"><person-group person-group-type="author"><name><surname>Fiore</surname><given-names>M.C.</given-names></name><name><surname>Bailey</surname><given-names>W.C.</given-names></name><name><surname>Cohen</surname><given-names>S.J.</given-names></name></person-group><chapter-title>Treating tobacco use and dependence</chapter-title><source>Clinical Practice Guideline</source><year>2000</year><publisher-name>US Department of Health and Human Services, Public Health Service</publisher-name><publisher-loc>Rockville (MD)</publisher-loc><comment>(June)</comment></element-citation></ref><ref id="bb0275"><element-citation publication-type="journal" id="rf0240"><person-group person-group-type="author"><name><surname>Gage</surname><given-names>B.F.</given-names></name><name><surname>Cardinalli</surname><given-names>A.B.</given-names></name><name><surname>Owens</surname><given-names>D.K.</given-names></name></person-group><article-title>Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation</article-title><source>Stroke</source><volume>29</volume><issue>6</issue><year>1998</year><fpage>1083</fpage><lpage>1091</lpage><pub-id pub-id-type="pmid">9626276</pub-id></element-citation></ref><ref id="bb0280"><element-citation publication-type="journal" id="rf0245"><person-group person-group-type="author"><name><surname>Gibbons</surname><given-names>R.D.</given-names></name><name><surname>Mann</surname><given-names>J.J.</given-names></name></person-group><article-title>Varenicline, smoking cessation, and neuropsychiatric adverse events</article-title><source>Am. J. Psychiatry</source><volume>170</volume><issue>12</issue><year>2013</year><fpage>1460</fpage><lpage>1467</lpage><comment>(Dec 1)</comment><pub-id pub-id-type="pmid">24030388</pub-id></element-citation></ref><ref id="bb0100"><element-citation publication-type="journal" id="rf0070"><person-group person-group-type="author"><name><surname>Gonzales</surname><given-names>D.</given-names></name><name><surname>Rennard</surname><given-names>S.I.</given-names></name><name><surname>Nides</surname><given-names>M.</given-names></name></person-group><article-title>Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs. sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial</article-title><source>JAMA</source><volume>296</volume><year>2006</year><fpage>47</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">16820546</pub-id></element-citation></ref><ref id="bb0105"><element-citation publication-type="journal" id="rf0250"><person-group person-group-type="author"><name><surname>Gonzales</surname><given-names>D.</given-names></name><name><surname>Hajek</surname><given-names>P.</given-names></name><name><surname>Pliamm</surname><given-names>L.</given-names></name></person-group><article-title>Re-treatment with varenicline for smoking cessation in smokers who have previously taken varenicline: a randomized, placebo-controlled trial</article-title><source>Clin. Pharmacol. Ther.</source><volume>96</volume><issue>3</issue><year>Sep 2014</year><fpage>390</fpage><lpage>396</lpage><comment>(Epub 2014 Jun 9)</comment><pub-id pub-id-type="pmid">24911368</pub-id></element-citation></ref><ref id="bb0110"><element-citation publication-type="book" id="rf0080"><person-group person-group-type="author"><name><surname>Gray</surname><given-names>C.</given-names></name><name><surname>Clarke</surname><given-names>P.</given-names></name><name><surname>Wolstenholme</surname><given-names>J.</given-names></name><name><surname>Wordsworth</surname><given-names>S.</given-names></name></person-group><chapter-title>Applied Methods of Cost-effectiveness Analysis in Healthcare</chapter-title><year>2010</year><publisher-name>Oxford University Press</publisher-name></element-citation></ref><ref id="bb0115"><element-citation publication-type="journal" id="rf0085"><person-group person-group-type="author"><name><surname>Hay</surname><given-names>J.W.</given-names></name><name><surname>Sterling</surname><given-names>K.L.</given-names></name></person-group><article-title>Cost effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease</article-title><source>Pharmacoeconomics</source><volume>23</volume><issue>2</issue><year>2005</year><comment>(133-14)</comment></element-citation></ref><ref id="bb0120"><element-citation publication-type="journal" id="rf0090"><person-group person-group-type="author"><name><surname>Hoogendoorn</surname><given-names>M.</given-names></name><name><surname>Welsing</surname><given-names>P.</given-names></name><name><surname>Rutten-van M&#x000f6;lken</surname><given-names>M.P.M.H.</given-names></name></person-group><article-title>Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands</article-title><source>Curr. Med. Res. Opin.</source><volume>24</volume><issue>1</issue><year>2008</year><fpage>51</fpage><lpage>61</lpage><comment>(Jan)</comment><pub-id pub-id-type="pmid">18021492</pub-id></element-citation></ref><ref id="bb0125"><element-citation publication-type="journal" id="rf0095"><person-group person-group-type="author"><name><surname>Howard</surname><given-names>P.</given-names></name><name><surname>Knight</surname><given-names>C.</given-names></name><name><surname>Boler</surname><given-names>A.</given-names></name><name><surname>Baker</surname><given-names>C.</given-names></name></person-group><article-title>Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO simulation model: application to a population of US adult smokers</article-title><source>Pharmacoeconomics</source><volume>26</volume><issue>6</issue><year>2008</year><fpage>497</fpage><lpage>511</lpage><pub-id pub-id-type="pmid">18489200</pub-id></element-citation></ref><ref id="bb0130"><element-citation publication-type="journal" id="rf0100"><person-group person-group-type="author"><name><surname>Igarashi</surname><given-names>A.</given-names></name><name><surname>Takuma</surname><given-names>H.</given-names></name><name><surname>Fukuda</surname><given-names>T.</given-names></name></person-group><article-title>Cost-utility analysis of varenicline, an oral smoking-cessation drug, in Japan</article-title><source>Pharmacoeconomics</source><volume>27</volume><issue>3</issue><year>2009</year><fpage>247</fpage><lpage>261</lpage><pub-id pub-id-type="pmid">19354344</pub-id></element-citation></ref><ref id="bb0135"><element-citation publication-type="other" id="rf0255"><article-title>Institut National d'Assurance Maladie-Invalidit&#x000e9;/Rijksinstituut voor ziekte- en invaliditeitsverzekering (RIZIV-INAMI)</article-title><comment>URL:</comment><ext-link ext-link-type="uri" xlink:href="http://www.riziv.fgov.be" id="ir0130">http://www.riziv.fgov.be</ext-link><comment>(Accessed October 2013)</comment></element-citation></ref><ref id="bb0140"><element-citation publication-type="journal" id="rf0105"><person-group person-group-type="author"><name><surname>Jorenby</surname><given-names>D.E.</given-names></name><name><surname>Hays</surname><given-names>J.T.</given-names></name><name><surname>Rigotti</surname><given-names>N.A.</given-names></name></person-group><article-title>Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs. placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial</article-title><source>JAMA</source><volume>296</volume><year>2006</year><fpage>56</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">16820547</pub-id></element-citation></ref><ref id="bb0145"><element-citation publication-type="journal" id="rf0260"><person-group person-group-type="author"><name><surname>Keating</surname><given-names>G.M.</given-names></name><name><surname>Lyseng-Williamson</surname></name></person-group><article-title>Varenicline. A pharmacoeconomic review of its use as an aid to smoking cessation</article-title><source>Pharmacoeconomics</source><volume>28</volume><issue>3</issue><year>2010</year><fpage>231</fpage><lpage>254</lpage><pub-id pub-id-type="pmid">20108995</pub-id></element-citation></ref><ref id="bb0150"><element-citation publication-type="journal" id="rf0110"><person-group person-group-type="author"><name><surname>Knight</surname><given-names>C.</given-names></name><name><surname>Marbaix</surname><given-names>S.</given-names></name><name><surname>Annemans</surname><given-names>L.</given-names></name></person-group><article-title>The cost-effectiveness of an extended course (12&#x000a0;+&#x000a0;12&#x000a0;weeks) of varenicline plus brief counselling compared with other reimbursed smoking cessation interventions in Belgium, from a public payer perspective</article-title><source>Acta Clin. Belg.</source><volume>67</volume><issue>6</issue><year>2012</year></element-citation></ref><ref id="bb0155"><element-citation publication-type="journal" id="rf0115"><person-group person-group-type="author"><name><surname>Krall</surname><given-names>E.A.</given-names></name><name><surname>Garvey</surname><given-names>A.J.</given-names></name><name><surname>Garcia</surname><given-names>R.I.</given-names></name></person-group><article-title>Smoking relapse after 2&#x000a0;years of abstinence: findings from the VA Normative Aging Study</article-title><source>Nicotine Tob. Res.</source><volume>4</volume><issue>1</issue><year>2002</year><fpage>95</fpage><lpage>100</lpage><pub-id pub-id-type="pmid">11906685</pub-id></element-citation></ref><ref id="bb0160"><element-citation publication-type="journal" id="rf0120"><person-group person-group-type="author"><name><surname>Linden</surname><given-names>K.</given-names></name><name><surname>Jormanainen</surname><given-names>V.</given-names></name><name><surname>Linna</surname><given-names>M.</given-names></name><name><surname>Sintonen</surname><given-names>H.</given-names></name><name><surname>Wilson</surname><given-names>K.</given-names></name><name><surname>Kotom&#x000e4;ki</surname><given-names>T.</given-names></name></person-group><article-title>Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers</article-title><source>Curr. Med. Res. Opin.</source><volume>26</volume><issue>3</issue><year>2010</year><fpage>549</fpage><lpage>560</lpage><comment>(Mar)</comment><pub-id pub-id-type="pmid">20050814</pub-id></element-citation></ref><ref id="bb0170"><element-citation publication-type="journal" id="rf0125"><person-group person-group-type="author"><name><surname>Lutz</surname><given-names>M.A.</given-names></name><name><surname>Lovato</surname><given-names>P.</given-names></name><name><surname>Cuesta</surname><given-names>G.</given-names></name></person-group><article-title>Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model</article-title><source>Hosp. Pract.</source><volume>40</volume><issue>1</issue><year>2012</year><fpage>24</fpage><lpage>34</lpage><comment>(Feb)</comment></element-citation></ref><ref id="bb0165"><element-citation publication-type="journal" id="rf0265"><person-group person-group-type="author"><name><surname>Mahmoudi</surname><given-names>M.</given-names></name><name><surname>Coleman</surname><given-names>C.I.</given-names></name><name><surname>Sobieraj</surname><given-names>D.M.</given-names></name></person-group><article-title>Systematic review of the cost-effectiveness of varenicline vs. bupropion for smoking cessation</article-title><source>Int. J. Clin. Pract.</source><volume>66</volume><issue>2</issue><year>2012</year><fpage>171</fpage><lpage>182</lpage><comment>(February)</comment><pub-id pub-id-type="pmid">22257042</pub-id></element-citation></ref><ref id="bb0175"><element-citation publication-type="journal" id="rf0130"><person-group person-group-type="author"><name><surname>Mannino</surname><given-names>D.M.</given-names></name><name><surname>Buist</surname><given-names>A.S.</given-names></name><name><surname>Petty</surname><given-names>T.L.</given-names></name><name><surname>Enright</surname><given-names>P.L.</given-names></name><name><surname>Redd</surname><given-names>S.C.</given-names></name></person-group><article-title>Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow-up study</article-title><source>Thorax</source><volume>58</volume><issue>5</issue><year>2003</year><fpage>388</fpage><lpage>393</lpage><pub-id pub-id-type="pmid">12728157</pub-id></element-citation></ref><ref id="bb0180"><element-citation publication-type="journal" id="rf0135"><person-group person-group-type="author"><name><surname>Mills</surname><given-names>E.J.</given-names></name><name><surname>Thorlund</surname><given-names>K.</given-names></name><name><surname>Eapen</surname><given-names>S.</given-names></name><name><surname>Wu</surname><given-names>P.</given-names></name><name><surname>Prochaska</surname><given-names>J.J.</given-names></name></person-group><article-title>Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis</article-title><source>Circulation</source><volume>129</volume><issue>1</issue><year>2014</year><fpage>28</fpage><lpage>41</lpage><comment>(Jan 7, Epub 2013 Dec 9)</comment><pub-id pub-id-type="pmid">24323793</pub-id></element-citation></ref><ref id="bb0185"><element-citation publication-type="journal" id="rf0270"><person-group person-group-type="author"><name><surname>Muls</surname><given-names>E.</given-names></name><name><surname>Van Ganse</surname><given-names>E.</given-names></name><name><surname>Closon</surname><given-names>M.C.</given-names></name></person-group><article-title>Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: comparison between Belgium and the United States of a projected risk model</article-title><source>Atherosclerosis</source><volume>137</volume><year>1998</year><fpage>S111</fpage><lpage>S116</lpage><comment>(Suppl.)</comment><pub-id pub-id-type="pmid">9694550</pub-id></element-citation></ref><ref id="bb0190"><element-citation publication-type="journal" id="rf0140"><person-group person-group-type="author"><name><surname>Nides</surname><given-names>M.</given-names></name><name><surname>Elbert</surname><given-names>D.</given-names></name></person-group><article-title>Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis</article-title><source>Am. J. Health Behav.</source><volume>32</volume><issue>6</issue><year>2008</year><fpage>664</fpage><lpage>675</lpage><pub-id pub-id-type="pmid">18442345</pub-id></element-citation></ref><ref id="bb0195"><element-citation publication-type="journal" id="rf0275"><person-group person-group-type="author"><name><surname>Orme</surname><given-names>M.E.</given-names></name><name><surname>Hogue</surname><given-names>S.L.</given-names></name><name><surname>Kennedy</surname><given-names>L.M.</given-names></name><name><surname>Paine</surname><given-names>A.C.</given-names></name><name><surname>Godfrey</surname><given-names>C.</given-names></name></person-group><article-title>Development of the health and economic consequences of smoking interactive model</article-title><source>Tob. Control.</source><volume>10</volume><issue>1</issue><year>2001</year><fpage>55</fpage><lpage>61</lpage><comment>(Mar)</comment><pub-id pub-id-type="pmid">11226362</pub-id></element-citation></ref><ref id="bb0200"><element-citation publication-type="book" id="rf0280"><person-group person-group-type="author"><name><surname>Pacolet</surname><given-names>J.</given-names></name><name><surname>De Coninck</surname><given-names>A.</given-names></name><name><surname>Hedebouw</surname><given-names>G.</given-names></name></person-group><chapter-title>De medische en niet-medische kosten van kankerpati&#x000eb;nten</chapter-title><source>HIVA report</source><year>2011</year><comment>(Available from URL: <ext-link ext-link-type="uri" xlink:href="http://hiva.kuleuven.be/nl/publicaties/publicatie_detail.php?id=3312" id="ir0135">http://hiva.kuleuven.be/nl/publicaties/publicatie_detail.php?id=3312</ext-link>)</comment></element-citation></ref><ref id="bb9000"><element-citation publication-type="journal" id="rf9275"><person-group person-group-type="author"><name><surname>Peto</surname><given-names>R.</given-names></name><name><surname>Darby</surname><given-names>S.</given-names></name><name><surname>Deo</surname><given-names>H.</given-names></name><name><surname>Silcocks</surname><given-names>P.</given-names></name><name><surname>Whitley</surname><given-names>E.</given-names></name><name><surname>Doll</surname><given-names>R.</given-names></name></person-group><article-title>Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies</article-title><source>BMJ.</source><volume>321</volume><issue>7257</issue><year>2000</year><fpage>323</fpage><lpage>329</lpage><comment>(Aug 5)</comment><pub-id pub-id-type="pmid">10926586</pub-id></element-citation></ref><ref id="bb0205"><element-citation publication-type="journal" id="rf0145"><person-group person-group-type="author"><name><surname>Spencer</surname><given-names>M.</given-names></name><name><surname>Briggs</surname><given-names>A.H.</given-names></name><name><surname>Grossman</surname><given-names>R.F.</given-names></name><name><surname>Rance</surname><given-names>L.</given-names></name></person-group><article-title>Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease</article-title><source>Pharmacoeconomics</source><volume>23</volume><issue>6</issue><year>2005</year><fpage>619</fpage><lpage>637</lpage><pub-id pub-id-type="pmid">15960557</pub-id></element-citation></ref><ref id="bb0210"><element-citation publication-type="journal" id="rf0150"><person-group person-group-type="author"><name><surname>Szende</surname><given-names>A.</given-names></name><name><surname>Svensson</surname><given-names>K.</given-names></name><name><surname>Stahl</surname><given-names>E.</given-names></name><name><surname>Meszaros</surname><given-names>A.</given-names></name><name><surname>Berta</surname><given-names>G.Y.</given-names></name></person-group><article-title>Psychometric and utility-based measures of health status of asthmatic patients with different disease control level</article-title><source>Pharmacoeconomics</source><volume>22</volume><issue>8</issue><year>2004</year><fpage>537</fpage><lpage>547</lpage><pub-id pub-id-type="pmid">15217309</pub-id></element-citation></ref><ref id="bb0215"><element-citation publication-type="other" id="rf0285"><person-group person-group-type="author"><name><surname>Technische Cel &#x02014; Cellule technique TCT</surname></name></person-group><article-title>Banque de donn&#x000e9;es nationales 2010</article-title><comment>Available from URL:</comment><ext-link ext-link-type="uri" xlink:href="https://tct.fgov.be/webetct/etct-web/" id="ir0140">https://tct.fgov.be/webetct/etct-web/</ext-link><comment>(online. Accessed October 2013)</comment></element-citation></ref><ref id="bb0220"><element-citation publication-type="journal" id="rf0155"><person-group person-group-type="author"><name><surname>Tengs</surname><given-names>T.O.</given-names></name><name><surname>Lin</surname><given-names>T.H.</given-names></name></person-group><article-title>A meta-analysis of quality-of-life estimates for stroke</article-title><source>Pharmacoeconomics</source><volume>21</volume><issue>3</issue><year>2003</year><fpage>191</fpage><lpage>200</lpage><pub-id pub-id-type="pmid">12558469</pub-id></element-citation></ref><ref id="bb0225"><element-citation publication-type="journal" id="rf0160"><person-group person-group-type="author"><name><surname>Thun</surname><given-names>M.J.</given-names></name><name><surname>Apicella</surname><given-names>L.F.</given-names></name><name><surname>Henley</surname><given-names>S.J.</given-names></name></person-group><article-title>Smoking vs other risk factors as the cause of smoking-attributable deaths: confounding in the courtroom</article-title><source>JAMA</source><volume>284</volume><year>2000</year><fpage>706</fpage><lpage>712</lpage><pub-id pub-id-type="pmid">10927778</pub-id></element-citation></ref><ref id="bb0230"><element-citation publication-type="journal" id="rf0290"><person-group person-group-type="author"><name><surname>Tonstad</surname><given-names>S.</given-names></name><name><surname>Tonnesen</surname><given-names>P.</given-names></name><name><surname>Hajek</surname><given-names>P.</given-names></name><name><surname>Williams</surname><given-names>K.E.</given-names></name><name><surname>Billing</surname><given-names>C.B.</given-names></name><name><surname>Reeves</surname><given-names>K.R.</given-names></name></person-group><article-title>Varenicline Phase 3 study Group, Effect of maintenance therapy with varenicline on smoking cessation : a randomized controlled trial</article-title><source>JAMA</source><volume>296</volume><issue>1</issue><year>2006</year><fpage>64</fpage><lpage>71</lpage><comment>(Jul 5)</comment><pub-id pub-id-type="pmid">16820548</pub-id></element-citation></ref><ref id="bb0235"><element-citation publication-type="journal" id="rf0165"><person-group person-group-type="author"><name><surname>Trippoli</surname><given-names>S.</given-names></name><name><surname>Vaiani</surname><given-names>M.</given-names></name><name><surname>Lucioni</surname><given-names>C.</given-names></name><name><surname>Messori</surname><given-names>A.</given-names></name></person-group><article-title>Quality of life and utility in patients with non-small cell lung cancer. Quality-of-life Study Group of the Master 2 Project in Pharmacoeconomics</article-title><source>Pharmacoeconomics</source><volume>19</volume><issue>8</issue><year>2001</year><fpage>855</fpage><lpage>863</lpage><pub-id pub-id-type="pmid">11596837</pub-id></element-citation></ref><ref id="bb0245"><element-citation publication-type="book" id="rf0295"><person-group person-group-type="author"><name><surname>Van den Bruel</surname><given-names>A.</given-names></name><name><surname>Cleemput</surname><given-names>I.</given-names></name><name><surname>Van Linden</surname><given-names>A.</given-names></name></person-group><chapter-title>Effectiviteit en kosten-effectiviteit van behandlingen voor rookstop</chapter-title><source>Report KCE</source><year>2004</year><comment>(Available from: <ext-link ext-link-type="uri" xlink:href="http://www.kce.fgov.be" id="ir0145">http://www.kce.fgov.be</ext-link>)</comment></element-citation></ref><ref id="bb0250"><element-citation publication-type="journal" id="rf0175"><person-group person-group-type="author"><name><surname>van Genugten</surname><given-names>M.L.</given-names></name><name><surname>Hoogenveen</surname><given-names>R.T.</given-names></name><name><surname>Mulder</surname><given-names>I.</given-names></name></person-group><article-title>Future burden and costs of smoking-related disease in the Netherlands: a dynamic modeling approach</article-title><source>Value Health</source><volume>6</volume><issue>4</issue><year>2003</year><fpage>494</fpage><lpage>499</lpage><pub-id pub-id-type="pmid">12859591</pub-id></element-citation></ref><ref id="bb0255"><element-citation publication-type="journal" id="rf0300"><person-group person-group-type="author"><name><surname>Ware</surname><given-names>J.H.</given-names></name><name><surname>Vetrovec</surname><given-names>G.W.</given-names></name><name><surname>Miller</surname><given-names>A.B.</given-names></name></person-group><article-title>Cardiovascular safety of varenicline: patient-level meta-analysis of randomized, blinded, placebo-controlled trials</article-title><source>Am. J. Ther.</source><volume>20</volume><issue>3</issue><year>2013</year><fpage>235</fpage><lpage>246</lpage><comment>(May&#x02013;June)</comment><pub-id pub-id-type="pmid">23615317</pub-id></element-citation></ref><ref id="bb0260"><element-citation publication-type="journal" id="rf0180"><person-group person-group-type="author"><name><surname>Wetter</surname><given-names>D.W.</given-names></name><name><surname>Cofta-Gunn</surname><given-names>L.</given-names></name><name><surname>Fouladi</surname><given-names>R.T.</given-names></name></person-group><article-title>Late relapse/sustained abstinence among former smokers: a longitudinal study</article-title><source>Prev. Med.</source><volume>39</volume><issue>6</issue><year>2004</year><fpage>1156</fpage><lpage>1163</lpage><pub-id pub-id-type="pmid">15539050</pub-id></element-citation></ref><ref id="bb0265"><element-citation publication-type="journal" id="rf0185"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>K.</given-names></name><name><surname>Hettle</surname><given-names>R.</given-names></name><name><surname>Marbaix</surname><given-names>S.</given-names></name></person-group><article-title>An economic evaluation based on a randomized placebo-controlled trial of varenicline in smokers with cardiovascular disease: results for Belgium, Spain, Portugal, and Italy</article-title><source>Eur. J. Prev. Cardiol.</source><volume>19</volume><issue>5</issue><year>2010</year><fpage>1173</fpage><lpage>1183</lpage><pub-id pub-id-type="pmid">21840967</pub-id></element-citation></ref><ref id="bb0270"><element-citation publication-type="journal" id="rf0305"><person-group person-group-type="author"><name><surname>Zimovetz</surname><given-names>E.A.</given-names></name><name><surname>Wilson</surname><given-names>K.</given-names></name><name><surname>Samuel</surname><given-names>M.</given-names></name></person-group><article-title>A review of cost-effectiveness of varenicline and comparison of cost-effectiveness of treatments for major smoking-related morbidities</article-title><source>J. Eval. Clin. Pract.</source><volume>17</volume><issue>2</issue><year>2011</year><fpage>288</fpage><lpage>297</lpage><pub-id pub-id-type="pmid">21029268</pub-id></element-citation></ref></ref-list><sec id="s0070" sec-type="supplementary-material"><label>Appendix A</label><title>Supplementary data</title><p><supplementary-material content-type="local-data" id="ec0005"><caption><p>Supplementary tables.</p></caption><media xlink:href="mmc1.docx"/></supplementary-material></p></sec><ack id="ac0005"><title>Acknowledgments</title><p>We would like to thank the vendor, PAREXEL-HERON, that updated, validated, ran and described the model used in this analysis.</p><p>We would also like to thank Christine Baker, Anna Araiza and Michael Lunney from Pfizer NY who reviewed the manuscript.</p></ack><fn-group><fn id="s0080" fn-type="supplementary-material"><label>Appendix A</label><p>Supplementary data to this article can be found online at <ext-link ext-link-type="doi" xlink:href="10.1016/j.pmedr.2015.03.004" id="ir0525">http://dx.doi.org/10.1016/j.pmedr.2015.03.004</ext-link>.</p></fn></fn-group></back><floats-group><fig id="f0005"><label>Fig.&#x000a0;1</label><caption><p>Schematic diagram of three-stage process of quitting and relapsing to smoking.</p></caption><graphic xlink:href="gr1"/></fig><fig id="f0010"><label>Fig.&#x000a0;2</label><caption><p>Graphical presentation of the health economic model.</p></caption><graphic xlink:href="gr2"/></fig><fig id="f0015"><label>Fig.&#x000a0;3</label><caption><p>Probabilistic sensitivity analysis based on 1000 replications.</p></caption><graphic xlink:href="gr3"/></fig><table-wrap id="t0005" position="float"><label>Table&#x000a0;1</label><caption><p>Clinical input data.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">SC interventions</th><th align="left">Efficacy (CAR 9&#x02013;52&#x000a0;weeks)</th><th align="left">Source</th><th align="left">Comments</th></tr></thead><tbody><tr><td colspan="4" align="left"><italic>Efficacy of smoking cessation interventions 1st line</italic></td></tr><tr><td align="left">Varenicline 1st line</td><td align="left">21.1%</td><td align="left"><xref rid="bb0055" ref-type="bibr">Cahill et al. (2013)</xref><break/><xref rid="bb0190" ref-type="bibr">Nides et al. (2008)</xref></td><td align="left">The relative effect of varenicline in comparison to placebo is 2.27 (Cahill et al.). This effect is applied to the efficacy of placebo from <xref rid="bb0190" ref-type="bibr">Nides et al. (2008)</xref> (9.3%&#x000a0;&#x02217;&#x000a0;2.27&#x000a0;=&#x000a0;21.1%).</td></tr><tr><td align="left">Bupropion 1st line</td><td align="left">15.7%</td><td align="left"><xref rid="bb0055" ref-type="bibr">Cahill et al. (2013)</xref><break/><xref rid="bb0190" ref-type="bibr">Nides et al. (2008)</xref></td><td align="left">The relative effect of bupropion in comparison to placebo is 1.69 (Cahill et al.). This effect is applied to the efficacy of placebo from <xref rid="bb0190" ref-type="bibr">Nides et al. (2008)</xref> (9.3%&#x000a0;&#x02217;&#x000a0;1.69&#x000a0;=&#x000a0;15.7%).</td></tr><tr><td align="left">NRT 1st line</td><td align="left">14.9%</td><td align="left"><xref rid="bb0055" ref-type="bibr">Cahill et al. (2013)</xref><break/><xref rid="bb0190" ref-type="bibr">Nides et al. (2008)</xref></td><td align="left">The relative effect of NRT in comparison to placebo is 1.60 (Cahill et al.). This effect is applied to the efficacy of placebo from <xref rid="bb0190" ref-type="bibr">Nides et al. (2008)</xref> (9.3%&#x000a0;&#x02217;&#x000a0;1.60&#x000a0;=&#x000a0;14.9%).</td></tr><tr><td align="left">Placebo 1st line</td><td align="left">9.3%</td><td align="left"><xref rid="bb0190" ref-type="bibr">Nides et al. (2008)</xref></td><td align="left">Pooled estimate of Phase III trials comparing varenicline to bupropion and placebo</td></tr><tr><td colspan="4" align="left">&#x02028;&#x02028;</td></tr><tr><td colspan="4" align="left"><italic>Efficacy of smoking cessation interventions 2nd line</italic></td></tr><tr><td align="left">Varenicline 2nd line</td><td align="left">20.1%</td><td align="left"><xref rid="bb0105" ref-type="bibr">Gonzales et al. (2014)</xref></td><td align="left">CAR at 52&#x000a0;weeks</td></tr><tr><td align="left">Bupropion 2nd line</td><td align="left">15.7%</td><td align="left">Assumption</td><td align="left">Assumed equivalent to 1st quit attempt</td></tr><tr><td align="left">NRT 2nd line</td><td align="left">14.9%</td><td align="left">Assumption</td><td align="left">Idem</td></tr><tr><td align="left">Placebo 2nd line</td><td align="left">3.3%</td><td align="left">Phase IV CSR</td><td align="left">CAR in 9&#x02013;52&#x000a0;weeks (secondary endpoint)</td></tr></tbody></table><table-wrap-foot><fn id="sp0065"><p>CAR&#x000a0;=&#x000a0;continuous abstinence rate.</p></fn><fn id="sp0070"><p>CSR&#x000a0;=&#x000a0;clinical study report (Pfizer data on file).</p></fn></table-wrap-foot></table-wrap><table-wrap id="t0010" position="float"><label>Table&#x000a0;2</label><caption><p>Relative risks for complications associated with smoking (never smokers&#x000a0;=&#x000a0;1).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Population</th><th colspan="2" align="left">RR of disease<hr/></th><th align="left">Source<hr/></th></tr><tr><th align="left">Current smokers</th><th align="left">Former smokers</th><th align="left"/></tr></thead><tbody><tr><td colspan="4" align="left"><italic>Chronic obstructive pulmonary disease</italic></td></tr><tr><td align="left">Males 18&#x02013;34&#x000a0;years</td><td align="char">1.0</td><td align="char">1.0</td><td align="left"><xref rid="bb0225" ref-type="bibr">Thun et al. (2000)</xref></td></tr><tr><td align="left">Males 35&#x02013;64&#x000a0;years</td><td align="char">10.8</td><td align="char">7.8</td></tr><tr><td align="left">Males 65&#x000a0;+&#x000a0;years</td><td align="char">10.8</td><td align="char">7.8</td></tr><tr><td align="left">Females 18&#x02013;34&#x000a0;years</td><td align="char">1.0</td><td align="char">1.0</td></tr><tr><td align="left">Females 35&#x02013;64&#x000a0;years</td><td align="char">12.3</td><td align="char">8.9</td></tr><tr><td align="left">Females 65&#x000a0;+&#x000a0;years</td><td align="char">12.3</td><td align="char">8.9</td></tr><tr><td colspan="4" align="left">&#x02028;&#x02028;</td></tr><tr><td colspan="4" align="left"><italic>Lung cancer</italic></td></tr><tr><td align="left">Males 18&#x02013;34&#x000a0;years</td><td align="char">1.0</td><td align="char">1.0</td><td align="left"><xref rid="bb0225" ref-type="bibr">Thun et al. (2000)</xref></td></tr><tr><td align="left">Males 35&#x02013;64&#x000a0;years</td><td align="char">21.3</td><td align="char">8.3</td></tr><tr><td align="left">Males 65&#x000a0;+&#x000a0;years</td><td align="char">21.3</td><td align="char">8.3</td></tr><tr><td align="left">Females 18&#x02013;34&#x000a0;years</td><td align="char">1.0</td><td align="char">1.0</td></tr><tr><td align="left">Females 35&#x02013;64&#x000a0;years</td><td align="char">12.5</td><td align="char">4.8</td></tr><tr><td align="left">Females 65&#x000a0;+&#x000a0;years</td><td align="char">12.5</td><td align="char">4.8</td></tr><tr><td colspan="4" align="left">&#x02028;&#x02028;</td></tr><tr><td colspan="4" align="left"><italic>Coronary heart disease</italic></td></tr><tr><td align="left">Males 18&#x02013;34&#x000a0;years</td><td align="char">1.0</td><td align="char">1.0</td><td align="left"><xref rid="bb0225" ref-type="bibr">Thun et al. (2000)</xref></td></tr><tr><td align="left">Males 35&#x02013;64&#x000a0;years</td><td align="char">2.6</td><td align="char">1.6</td></tr><tr><td align="left">Males 65&#x000a0;+&#x000a0;years</td><td align="char">1.5</td><td align="char">1.2</td></tr><tr><td align="left">Females 18&#x02013;34&#x000a0;years</td><td align="char">1.0</td><td align="char">1.0</td></tr><tr><td align="left">Females 35&#x02013;64&#x000a0;years</td><td align="char">3.2</td><td align="char">1.4</td></tr><tr><td align="left">Females 65&#x000a0;+&#x000a0;years</td><td align="char">1.7</td><td align="char">1.4</td></tr><tr><td colspan="4" align="left">&#x02028;&#x02028;</td></tr><tr><td colspan="4" align="left"><italic>Stroke</italic></td></tr><tr><td align="left">Males 18&#x02013;34&#x000a0;years</td><td align="char">1.0</td><td align="char">1.0</td><td align="left"><xref rid="bb0225" ref-type="bibr">Thun et al. (2000)</xref></td></tr><tr><td align="left">Males 35&#x02013;64&#x000a0;years</td><td align="char">2.4</td><td align="char">1.0</td></tr><tr><td align="left">Males 65&#x000a0;+&#x000a0;years</td><td align="char">1.5</td><td align="char">1.0</td></tr><tr><td align="left">Females 18&#x02013;34&#x000a0;years</td><td align="char">1.0</td><td align="char">1.0</td></tr><tr><td align="left">Females 35&#x02013;64&#x000a0;years</td><td align="char">3.8</td><td align="char">1.5</td></tr><tr><td align="left">Females 65&#x000a0;+&#x000a0;years</td><td align="char">1.6</td><td align="char">1.2</td></tr><tr><td colspan="4" align="left">&#x02028;&#x02028;</td></tr><tr><td colspan="4" align="left"><italic>Asthma exacerbations</italic></td></tr><tr><td align="left">Males 18&#x02013;34&#x000a0;years</td><td align="char">1.4</td><td align="char">1.0</td><td align="left"><xref rid="bb0060" ref-type="bibr">Cassino et al. (1999)</xref></td></tr><tr><td align="left">Males 35&#x02013;64&#x000a0;years</td><td align="char">1.0</td><td align="char">1.0</td></tr><tr><td align="left">Males 65&#x000a0;+&#x000a0;years</td><td align="char">1.1</td><td align="char">1.0</td></tr><tr><td align="left">Females 18&#x02013;34&#x000a0;years</td><td align="char">1.4</td><td align="char">1.0</td></tr><tr><td align="left">Females 35&#x02013;64&#x000a0;years</td><td align="char">1.0</td><td align="char">1.0</td></tr><tr><td align="left">Females 65&#x000a0;+&#x000a0;years</td><td align="char">1.1</td><td align="char">1.0</td></tr></tbody></table></table-wrap><table-wrap id="t0015" position="float"><label>Table&#x000a0;3</label><caption><p>Cost data.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="4" align="left">Cost of therapy<hr/></th></tr><tr><th align="left">Therapy</th><th align="left">Cost per quit attempt (&#x020ac;)</th><th align="left">Source</th><th align="left">Comments</th></tr></thead><tbody><tr><td align="left">Varenicline (Champix)</td><td align="char">246.81</td><td align="left"><ext-link ext-link-type="uri" xlink:href="http://www.cbip.be" id="ir0080">www.cbip.be</ext-link><break/><ext-link ext-link-type="uri" xlink:href="http://www.inami.fgov.be" id="ir0085">www.inami.fgov.be</ext-link></td><td align="left">Based on public price of titration pack (2&#x000a0;weeks) and 10&#x000a0;week pack</td></tr><tr><td align="left">NRT</td><td align="char">230.77</td><td/><td align="left">Based on a weighted daily cost of 2.75&#x020ac; times 84&#x000a0;days</td></tr><tr><td align="left">Bupropion (Zyban)</td><td align="char">170.40</td><td align="left"><ext-link ext-link-type="uri" xlink:href="http://www.cbip.be" id="ir0090">www.cbip.be</ext-link><break/><ext-link ext-link-type="uri" xlink:href="http://www.inami.fgov.be" id="ir0095">www.inami.fgov.be</ext-link></td><td align="left">Based on public price of 2 packs of 18&#x000a0;days and 1 pack of 50&#x000a0;days</td></tr><tr><td colspan="4" align="left">&#x02028;&#x02028;</td></tr><tr><td colspan="4" align="left">Cost of smoking-related diseases</td></tr><tr><td colspan="4"><hr/></td></tr><tr><td align="left">Diseases</td><td align="left">Cost 1st year (&#x020ac;)</td><td align="left">Follow-up cost per year (&#x020ac;)</td><td align="left">Source</td></tr><tr><td colspan="4"><hr/></td></tr><tr><td align="left">Stroke</td><td align="left">16,501&#x020ac; (8,651&#x020ac; hospital stay&#x000a0;+&#x000a0;7,850&#x020ac; for 1st year follow-up)</td><td align="char">4,419&#x020ac;</td><td align="left">Acute: mean APR-DRG 045/046 (inflated year 2010)<break/>(<ext-link ext-link-type="uri" xlink:href="http://www.tct.fgov.be" id="ir0100">www.tct.fgov.be</ext-link>)<break/>Follow-up: <xref rid="bb0005" ref-type="bibr">Annemans et al. (2003)</xref>, inflated</td></tr><tr><td align="left">CHD (myocardial infarction &#x00026; angina)</td><td align="left">8,487&#x020ac; (4,395&#x020ac; hospital stay&#x000a0;+&#x000a0;4,091&#x020ac; for 1st year follow-up)</td><td align="char">2,148&#x020ac;</td><td align="left">Acute: mean APR-DRG 190 (MI) &#x00026; 202 (angina), inflated year 2010<break/>(<ext-link ext-link-type="uri" xlink:href="http://www.tct.fgov.be" id="ir0105">www.tct.fgov.be</ext-link>)<break/>Follow-up: <xref rid="bb0005" ref-type="bibr">Annemans et al. (2003)</xref>, inflated</td></tr><tr><td align="left">Asthma exacerbations</td><td align="left">2,861&#x020ac;</td><td/><td align="left">Acute: APR-DRG 141, inflated year 2010<break/><ext-link ext-link-type="uri" xlink:href="http://www.tct.fgov.be" id="ir0110">http://www.tct.fgov.be</ext-link></td></tr><tr><td align="left">COPD</td><td align="left">2,186&#x020ac;</td><td align="char">2,186&#x020ac;</td><td align="left">Mean annual cost <xref rid="bb0050" ref-type="bibr">Caekelbergh et al. (2005)</xref>, inflated</td></tr><tr><td align="left">Lung cancer</td><td align="left">10,765&#x020ac;</td><td align="char">10,765&#x020ac;</td><td align="left">Mean annual cost <xref rid="bb0200" ref-type="bibr">Pacolet et al. (2011)</xref></td></tr></tbody></table></table-wrap><table-wrap id="t0020" position="float"><label>Table&#x000a0;4</label><caption><p>Utilities associated with smoking- related diseases.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Smoking-related diseases</th><th align="left">Utility first year</th><th align="left">Utility subsequent years</th><th align="left">Source</th></tr></thead><tbody><tr><td align="left">Chronic obstructive pulmonary disease</td><td align="char">0.76</td><td align="char">0.76</td><td align="left">(<xref rid="bb0175" ref-type="bibr">Mannino et al. (2003)</xref>; <xref rid="bb0205" ref-type="bibr">Spencer et al. (2005)</xref>)</td></tr><tr><td align="left">Lung cancer</td><td align="char">0.61</td><td align="char">0.50</td><td align="left"><xref rid="bb0235" ref-type="bibr">Trippoli et al. (2001)</xref></td></tr><tr><td colspan="4" align="left">&#x02028;&#x02028;</td></tr><tr><td align="left"/><td align="left">For first event</td><td align="left">For subsequent event</td><td align="left"/></tr><tr><td colspan="4"><hr/></td></tr><tr><td align="left">Coronary heart disease</td><td align="char">0.76</td><td align="char">0.76</td><td align="left"><xref rid="bb0115" ref-type="bibr">Hay and Sterling (2005)</xref></td></tr><tr><td align="left">Stroke</td><td align="char">0.74</td><td align="char">0.15</td><td align="left">(<xref rid="bb0075" ref-type="bibr">Duncan et al. (2000)</xref>; <xref rid="bb0275" ref-type="bibr">Gage et al. (1998)</xref>; <xref rid="bb0220" ref-type="bibr">Tengs and Lin (2003)</xref>)</td></tr><tr><td align="left">Asthma exacerbation</td><td align="char">0.52</td><td align="char">0.52</td><td align="left"><xref rid="bb0210" ref-type="bibr">Szende et al. (2004)</xref></td></tr></tbody></table></table-wrap><table-wrap id="t0025" position="float"><label>Table&#x000a0;5</label><caption><p>Results.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><hr/></th><th colspan="4" align="left">2QA varenicline compared with<hr/></th></tr><tr><th align="left">Costs (000&#x020ac;)</th><th align="left">2QA NRT</th><th align="left">2QA bupropion</th><th align="left">2QA placebo</th><th align="left">1QA varenicline</th></tr></thead><tbody><tr><td align="left">COPD cost</td><td align="char">&#x02212;&#x000a0;160</td><td align="char">&#x02212;&#x000a0;137</td><td align="char">&#x02212;&#x000a0;416</td><td align="char">&#x02212;&#x000a0;239</td></tr><tr><td align="left">Lung cancer cost</td><td align="char">&#x02212;&#x000a0;28</td><td align="char">&#x02212;&#x000a0;24</td><td align="char">&#x02212;&#x000a0;74</td><td align="char">&#x02212;&#x000a0;42</td></tr><tr><td align="left">CHD cost</td><td align="char">&#x02212;&#x000a0;63</td><td align="char">&#x02212;&#x000a0;54</td><td align="char">&#x02212;&#x000a0;165</td><td align="char">&#x02212;&#x000a0;94</td></tr><tr><td align="left">Stroke cost</td><td align="char">&#x02212;&#x000a0;43</td><td align="char">&#x02212;&#x000a0;37</td><td align="char">&#x02212;&#x000a0;112</td><td align="char">&#x02212;&#x000a0;64</td></tr><tr><td align="left">Total difference in smoking-related disease cost</td><td align="char">&#x02212;&#x000a0;295</td><td align="char">&#x02212;&#x000a0;251</td><td align="char">&#x02212;&#x000a0;766</td><td align="char">&#x02212;&#x000a0;440</td></tr><tr><td align="left">Total difference incl. drug cost</td><td align="char">&#x02212;&#x000a0;275</td><td align="char">&#x02212;&#x000a0;118</td><td align="char">&#x02212;&#x000a0;316</td><td align="char">&#x02212;&#x000a0;237</td></tr><tr><td align="left">Effects</td><td colspan="4" align="left"/></tr><tr><td align="left">QALYs</td><td align="char">74</td><td align="char">63</td><td align="char">193</td><td align="char">111</td></tr><tr><td align="left">LYs</td><td align="char">56</td><td align="char">48</td><td align="char">146</td><td align="char">84</td></tr></tbody></table><table-wrap-foot><fn><p>QA: quit attempt; COPD: chronic obstructive pulmonary disease; CHD: coronary heart disease (myocardial infarction and angina); NRT: nicotine replacement therapy; QALY: quality-adjusted life year; and LY: life year.</p></fn></table-wrap-foot></table-wrap></floats-group></article>